Ivabradine Bristol Laboratories

Ivabradine, the active ingredient in Ivabradine Bristol Laboratories, is a If channel inhibitor presented as an oral formulation for oral use. It treats chronic stable angina pectoris and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradine Bristol Laboratories as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine is used in cardiovascular conditions that involve excessive heart rate.

- Chronic stable angina pectoris: lowers heart rate to reduce the frequency of angina attacks. - Heart failure with reduced ejection fraction: improves symptoms and may decrease hospitalisation by controlling heart rate. - Coronary artery disease: helps manage heart rate when other rate‑controlling agents are unsuitable.

Adverse reactions are reported across a range of frequencies.

Common Side Effects: - Bradycardia: resting heart rate falls below the desired range. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or vertigo: especially on standing. - Fatigue: general feeling of tiredness. - Blurred vision: temporary visual acuity changes.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Severe hypotension leading to syncope. - Worsening heart failure symptoms. - Allergic reactions such as rash or angioedema. - Hepatic dysfunction with elevated liver enzymes.

Before prescribing ivabradine, clinicians should consider several safety factors.

- Cardiac monitoring: assess baseline heart rate and rhythm. - Concomitant beta‑blockers: avoid excessive heart‑rate reduction. - Severe hepatic impairment: use with caution or avoid. - Pregnancy: safety not established; weigh benefits against risks. - Renal impairment: evaluate renal function and adjust if needed. - Store at ambient temperature: keep in the original pack, protect from moisture.

Ivabradine may interact with other medicines that affect heart rate or its metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels. - Other heart‑rate‑lowering agents (beta‑blockers, digoxin): risk of excessive bradycardia. - Strong CYP3A4 inducers (e.g., rifampicin): reduce ivabradine efficacy.

Moderate Interactions (Monitor Closely):\n- Calcium channel blockers (verapamil, diltiazem): may raise ivabradine concentrations. - Antihypertensives: additive blood‑pressure‑lowering effect. - QT‑prolonging drugs: monitor ECG for arrhythmia risk.